Our StrategyVision-Driven Innovationin Drug & Cell Delivery
At Likarda, we’re reshaping the future of therapeutics by solving some of the most complex delivery and formulation challenges in healthcare. Our patented Core-Shell Spherification® (CSS®) platform enables long-acting injectables, immune-shielded delivery, and enhanced therapeutic viability—all while maintaining full biocompatibility and safety.
A Platform-First Commercialization Model
As a pure-play delivery platform company, Likarda partners exclusively with biopharma, biotech, and CDMOs to bring next-generation therapies to life. We do not develop our own therapeutics—ensuring we remain laser-focused and fully aligned with our partners’ success across a wide spectrum of modalities.
Strategic Validation in Three High-Impact Categories:
Biologics & Peptides
We enable sustained-release formulations for fragile proteins, hormones, and peptides—reducing dosing frequency, improving patient compliance, and extending therapeutic duration.
Cell & Gene Therapies
Our platform delivers immune-shielded, cryopreservation-free cell therapy products, supporting off-the-shelf logistics and enhanced in vivo viability for allogeneic and gene-modified cells.
Regenerative Medicine
CSS® technology creates optimized microenvironments for stem cells, iPSCs, MSCs, and extracellular vesicles, enhancing retention, functionality, and survival following in vivo delivery.
Built to Scale. Built to Partner.
Each engagement is structured to:
- Expand our growing intellectual property portfolio
- De-risk regulatory pathways for our partners
- Extend product lifecycles through differentiated delivery
We operate behind the scenes—and measure our success by the impact and adoption of our partners’ therapies.
Strategic Partnerships & Licensing
Our partnership-first model is designed to scale impact across the ecosystem. We collaborate with:
- Biopharma innovators seeking differentiated delivery systems
- CDMOs and platform integrators for clinical and commercial manufacturing
- Academic and clinical researchers exploring new therapeutic frontiers
Through these collaborations, we accelerate co-development, drive market adoption, and unlock the full commercial potential of our CSS® platform.
Our Partners
Scalable Manufacturing
With a closed-loop, modular manufacturing system launching in 2026, we are enabling:
- GMP-compliant encapsulation at clinical and commercial scale
- Standardized process validation for regulatory alignment
- Custom formulations with consistent bead size, purity, and release kinetics
De-risking Regulatory Pathways
Our platform is built on GRAS-designated, biocompatible materials, reducing regulatory complexity. Early use in preclinical studies, combined with robust process controls, supports both 505(b)(2) and BLA regulatory strategies.
Rather than altering the active ingredient, we encapsulate it within a polymer mesh—streamlining development and simplifying the 505(b)(2) regulatory pathway.
Partner with Likarda
to unlock the next generation of injectable therapies. Whether you’re formulating a fragile biologic, scaling a cell therapy, or looking to de-risk your development strategy—our team is ready to help.